PMID- 28378435
OWN - NLM
STAT- MEDLINE
DCOM- 20180515
LR  - 20181022
IS  - 1460-9568 (Electronic)
IS  - 0953-816X (Linking)
VI  - 45
IP  - 11
DP  - 2017 Jun
TI  - A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, 
      prevents the shift to a drug-dependent state and the expression of withdrawal 
      aversions in rodents.
PG  - 1410-1417
LID - 10.1111/ejn.13572 [doi]
AB  - Despite several studies suggesting the therapeutic use of 5-hydroxytryptamine 
      receptors type 2A (5-HT(2A) ) agonists in the treatment of substance use 
      disorders, the neurobiological basis accounting for such effects are still 
      unknown. It has been observed that chronic exposure to drugs of abuse produces 
      molecular and cellular adaptations in ventral tegmental area (VTA) neurons, 
      mediated by brain-derived neurotrophic factor (BDNF). These BDNF-induced 
      adaptations in the VTA are associated with the establishment of aversive 
      withdrawal motivation that leads to a drug-dependent state. Growing evidence 
      suggests that 5-HT(2A) receptor signaling can regulate the expression of BDNF in 
      the brain. In this study, we observed that a single systemic or intra-VTA 
      administration of a 5-HT(2A) agonist in rats and mice blocks both the aversive 
      conditioned response to drug withdrawal and the mechanism responsible for 
      switching from a drug-naive to a drug-dependent motivational system. Our results 
      suggest that 5-HT(2A) agonists could be used as therapeutic agents to reverse a 
      drug dependent state, as well as inhibiting the aversive effects produced by drug 
      withdrawal.
CI  - (c) 2017 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
FAU - Vargas-Perez, Hector
AU  - Vargas-Perez H
AUID- ORCID: 0000-0002-9907-7192
AD  - Institute of Medical Science, University of Toronto, 1130-160 College St, 
      Toronto, ON, M5S 3E1, Canada.
AD  - The Nierika Intercultural Medicine Institute, Ocuilan, Estado de Mexico, Mexico.
AD  - Postgrado en Ciencias Cognitivas, Universidad Autonoma del Estado de Morelos, 
      Cuernavaca, Morelos, Mexico.
FAU - Grieder, Taryn E
AU  - Grieder TE
AUID- ORCID: 0000-0003-4282-6049
AD  - Institute of Medical Science, University of Toronto, 1130-160 College St, 
      Toronto, ON, M5S 3E1, Canada.
FAU - Ting-A-Kee, Ryan
AU  - Ting-A-Kee R
AD  - Institute of Medical Science, University of Toronto, 1130-160 College St, 
      Toronto, ON, M5S 3E1, Canada.
FAU - Maal-Bared, Geith
AU  - Maal-Bared G
AD  - Institute of Medical Science, University of Toronto, 1130-160 College St, 
      Toronto, ON, M5S 3E1, Canada.
FAU - Chwalek, Michal
AU  - Chwalek M
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
FAU - van der Kooy, Derek
AU  - van der Kooy D
AD  - Institute of Medical Science, University of Toronto, 1130-160 College St, 
      Toronto, ON, M5S 3E1, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170504
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hallucinogens)
RN  - 0 (Serotonin 5-HT2 Receptor Antagonists)
RN  - 0 (Tryptamines)
RN  - 8BLF220HX1 (4-acetoxy-dimethyltryptamine)
RN  - WUB601BHAA (N,N-Dimethyltryptamine)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Hallucinogens/administration & dosage/*therapeutic use
MH  - Heroin Dependence/*drug therapy/prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - N,N-Dimethyltryptamine/administration & dosage/*analogs & derivatives/therapeutic 
      use
MH  - Rats
MH  - Rats, Wistar
MH  - Serotonin 5-HT2 Receptor Antagonists/administration & dosage/*therapeutic use
MH  - Substance Withdrawal Syndrome/*drug therapy/prevention & control
MH  - Tryptamines/administration & dosage/*therapeutic use
MH  - Ventral Tegmental Area/metabolism
OTO - NOTNLM
OT  - VTA
OT  - addiction
OT  - hallucinogen
OT  - neural plasticity
EDAT- 2017/04/06 06:00
MHDA- 2018/05/16 06:00
CRDT- 2017/04/06 06:00
PHST- 2016/12/22 00:00 [received]
PHST- 2017/03/23 00:00 [revised]
PHST- 2017/03/24 00:00 [accepted]
PHST- 2017/04/06 06:00 [pubmed]
PHST- 2018/05/16 06:00 [medline]
PHST- 2017/04/06 06:00 [entrez]
AID - 10.1111/ejn.13572 [doi]
PST - ppublish
SO  - Eur J Neurosci. 2017 Jun;45(11):1410-1417. doi: 10.1111/ejn.13572. Epub 2017 May 
      4.